Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Viatris

Viatris Stock: Is VTRS Outperforming the Health Care Sector?

As Viatris has outperformed the broader health care sector over the past year, and analysts remain moderately optimistic about the stock’s prospects.

Barchart

What Are Wall Street Analysts' Target Price for Viatris Stock?

Though Viatris has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Barchart

Viatris Earnings Preview: What to Expect

Viatris is set to report its fourth-quarter earnings soon, with analysts forecasting a slight decline in profits.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Is Viatris Stock Outperforming the Dow?

As Viatris has outperformed the Dow recently, analysts remain moderately optimistic about the stock’s prospects.

Barchart

Viatris Stock: Is Wall Street Bullish or Bearish?

Viatris has underperformed the broader market in recent months, and analysts’ outlook remains guarded as the company executes on its transformation efforts.

Barchart

Is Viatris Stock Underperforming the Nasdaq?

Viatris has lagged the broader Nasdaq Composite over the past year, and Wall Street sentiment toward the stock remains guarded.

Barchart

Viatris Stock: Analyst Estimates & Ratings

Viatris has considerably underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

What to Expect From Viatris' Next Quarterly Earnings Report

Viatris is all set to release its fiscal second-quarter earnings next month, and analysts project a double-digit earnings drop.

Barchart

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

As the pharmaceutical industry increasingly focuses on developing targeted treatments for niche conditions, Viatris Inc. (NASDAQ:VTRS) on Friday announced topline data from a Phase 3 study evaluating the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis.

Benzinga

Is Viatris Stock Underperforming the S&P 500?

Viatris has significantly underperformed the S&P 500 over the past year, and analysts remain cautious about the stock’s prospects.

Barchart

Do Wall Street Analysts Like Viatris Stock?

Viatris has underperformed the broader market over the past year, and analysts remain skeptical of the stock’s future potential.

Barchart

What to Expect From Viatris' Q1 2025 Earnings Report

Viatris is scheduled to report its first-quarter results next month, and analysts expect a double-digit earnings drop.

Barchart

How Is Viatris’ Stock Performance Compared to Other Biotech Stocks?

Over the past six months, Viatris has lagged behind its biotech peers, and Wall Street analysts continue to exercise caution regarding the stock's future outlook.

Barchart

Viatris Stock Outlook: Is Wall Street Bullish or Bearish?

As Viatris has trailed the broader market over the past year, analysts are skeptical about its future outlook.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Here's What to Expect From Viatris' Next Earnings Report

Viatris is scheduled to release its fourth-quarter earnings next month, and analysts anticipate a profit dip.

Barchart

Viatris Stock: Is VTRS Outperforming the Healthcare Sector?

Despite Viatris’ recent outperformance relative to its broader sector, Wall Street analysts remain cautious about the stock’s prospects.

The Guardian - UK

More ‘discreet’ Viagra-type drug could soon be available in Britain

US company Viatris has applied for a UK trademark for wafer-like film that dissolves in the mouth

MarketBeat

2 Generic Drug Stocks Ready to Surge in 2025

Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Are Wall Street Analysts Predicting Viatris Stock Will Climb or Sink?

Due to Viatris’ underperformance relative to the broader S&P 500 Index over the past year, Wall Street analysts remain cautious about the stock’s prospects.

Barchart

Earnings Preview: What to Expect From Viatris' Report

Viatris is all set to announce its third-quarter results next month, with analysts predicting a double-digit decline in the company's earnings.

Barchart

How To Spot Good Value Stocks In A Sea Of Noise

Explore why traditional value investing often falls short and how catalysts can transform undervalued stocks into lucrative investments.

Barchart

Is Viatris Stock Underperforming the Dow?

Viatris has underperformed the Dow Jones Industrial Average over the past year, and analysts remain cautious about the stock’s prospects.

Barchart

Is Wall Street Bullish or Bearish on Viatris' Stock?

Viatris has underperformed the broader market over the past year, and Wall Street analysts are cautious about the stock’s prospects.

Barchart

Viatris Quarterly Earnings Preview: What You Need to Know

Viatris is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit dip.

Barchart

Stocks Close Higher on Fed Rate Cut Optimism

The S&P 500 Index ($SPX ) (SPY ) Thursday closed up +0.51%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.85%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.16%. US stock indexes on Thursday settled higher, with the S&P 500 climbing to a...

1 2 3

People

Daly

94 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.